Replies to post #55690 on Biotech Values

[rsox]

the departure of a cfo in a company like rprx could very well mean that they are a done deal.....theyre going to be taken out, and he is down the road because an opportunity showed up and one can not pass up on opps....imho.

one mans guesstimation is as good as anothers.
we're all just handicapping based on what we think we know with regards to drugs and drug mkts and based on the sellmanship of the ceo and the mouthpieces who are master story tellers and share salesmen.

only the shadow knows for sure.

[DewDiligence]

>a CFO leaving is a warning sign, but in profitless biotechs there is less pressure to manipulate or cookie jar earnings or accruals.<

Nonetheless, the canary in the mine metaphor still applies because the CFO typically has less to gain—and more to lose—than other corporate executives by remaining with a biotech company whose prospects are sinking. (When two CFO’s leave within a short time, as was the case with DNDN, it’s an especially bad sign.)

By the way, the one who deserves credit for elucidating the the canary in the mine metaphor for CFO's is Dubi (a.k.a. midastouch017), not me. Regards, Dew

[DewDiligence]

>I'd like YOU to give US some scenarios instead of asking RPRX longs to explain what could easily be a matter of organizational paperwork.<

That’s pretty silly. If RPRX’s management is not telling investors the whole story about the phase-3 clinical programs and prior clinical data for Proellex, it’s not my problem—it’s yours.